Acrux Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARUXF research report →
Companywww.acrux.com.au
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause.
- CEO
- John Warmbrunn
- IPO
- 2010
- Employees
- 43
- HQ
- West Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $6.87M
- P/E
- -1.74
- P/S
- 1.46
- P/B
- 3.42
- EV/EBITDA
- -1.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 56.94%
- Op Margin
- -185.41%
- Net Margin
- -83.81%
- ROE
- -211.88%
- ROIC
- -120.27%
Growth & Income
- Revenue
- $1.19M · -76.63%
- Net Income
- $-5,945,000 · -2.50%
- EPS
- $-0.02 · 15.50%
- Op Income
- $-8,972,000
- FCF YoY
- -19.59%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.98
- Avg Volume
- 1.16K
Get TickerSpark's AI analysis on ARUXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ARUXF Coverage
We haven't published any research on ARUXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARUXF Report →